S. Andrew

8.4k total citations · 1 hit paper
84 papers, 4.2k citations indexed

About

S. Andrew is a scholar working on Genetics, Molecular Biology and Cancer Research. According to data from OpenAlex, S. Andrew has authored 84 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Genetics, 27 papers in Molecular Biology and 24 papers in Cancer Research. Recurrent topics in S. Andrew's work include Glioma Diagnosis and Treatment (58 papers), Cancer, Hypoxia, and Metabolism (13 papers) and Cancer Genomics and Diagnostics (11 papers). S. Andrew is often cited by papers focused on Glioma Diagnosis and Treatment (58 papers), Cancer, Hypoxia, and Metabolism (13 papers) and Cancer Genomics and Diagnostics (11 papers). S. Andrew collaborates with scholars based in United States, Japan and Netherlands. S. Andrew's co-authors include Tracy T. Batchelor, B Bernstein, Richard P. Koche, Eric M. Mendenhall, Manching Ku, Patrick Y. Wen, A. John Iafrate, Daniel P. Cahill, Esther Rheinbay and Simon Kasif and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

S. Andrew

84 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Genomewide Analysis of PRC1 and PRC2 Occupancy Identifies Two Classes of Bivalent Domains

2008 787 citations Esther Rheinbay, S. Andrew et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S. Andrew United States	34	2.2k	1.6k	885	741	612	84	4.2k
Dietmar Krex Germany	32	2.1k 0.9×	2.2k 1.4×	1.1k 1.3×	558 0.8×	495 0.8×	84	4.5k
Hendrikus J. Dubbink Netherlands	36	1.3k 0.6×	1.8k 1.1×	1.3k 1.4×	701 0.9×	680 1.1×	111	4.0k
Motoo Nagane Japan	28	2.5k 1.1×	1.3k 0.8×	959 1.1×	1.3k 1.8×	371 0.6×	113	4.3k
Keishi Makino Japan	27	1.5k 0.7×	1.4k 0.9×	583 0.7×	1.0k 1.4×	701 1.1×	95	4.2k
Joon H. Uhm United States	37	1.7k 0.8×	2.1k 1.3×	1.1k 1.3×	907 1.2×	425 0.7×	127	4.4k
Akitake Mukasa Japan	29	2.3k 1.0×	1.9k 1.2×	1.4k 1.5×	883 1.2×	485 0.8×	179	5.2k
Frits Thorsen Norway	36	1.6k 0.7×	1.2k 0.8×	972 1.1×	955 1.3×	320 0.5×	84	4.0k
Yukihiko Sonoda Japan	32	1.6k 0.7×	2.2k 1.4×	642 0.7×	596 0.8×	492 0.8×	224	4.6k
Vinay K. Puduvalli United States	38	1.9k 0.9×	2.2k 1.4×	1.2k 1.4×	934 1.3×	354 0.6×	170	4.6k
David N. Louis United States	22	1.4k 0.6×	1.9k 1.2×	781 0.9×	623 0.8×	904 1.5×	26	3.5k

Countries citing papers authored by S. Andrew

Since Specialization

Citations

This map shows the geographic impact of S. Andrew's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Andrew with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Andrew more than expected).

Fields of papers citing papers by S. Andrew

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Andrew. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Andrew. The network helps show where S. Andrew may publish in the future.

Co-authorship network of co-authors of S. Andrew

This figure shows the co-authorship network connecting the top 25 collaborators of S. Andrew. A scholar is included among the top collaborators of S. Andrew based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Andrew. S. Andrew is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Andrew, S. & Paul J. Thuluvath. (2023). The Role of Endoscopy for Primary and Secondary Prophylaxis of Variceal Bleeding. Gastrointestinal Endoscopy Clinics of North America. 34(2). 231–248. 1 indexed citations

Yekula, Anudeep, Tiffaney Hsia, Robert R. Kitchen, et al.. (2023). Longitudinal analysis of serum-derived extracellular vesicle RNA to monitor dacomitinib treatment response in EGFR-amplified recurrent glioblastoma patients. Neuro-Oncology Advances. 5(1). vdad104–vdad104. 2 indexed citations

Blakeley, Jaishri O., Stuart A. Grossman, S. Andrew, et al.. (2018). Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma. Clinical Cancer Research. 25(1). 73–79. 18 indexed citations

Andronesi, Ovidiu C., Isabel Arrillaga‐Romany, Ina Ly, et al.. (2018). Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. Nature Communications. 9(1). 1474–1474. 99 indexed citations

Andrew, S., et al.. (2018). Contrast blush on CT is a poor predictor of active bleeding on pelvic angiography. SHILAP Revista de lepidopterología. 1(3). e009–e009. 4 indexed citations

Patel, Sohil H., Laila Poisson, Daniel J. Brat, et al.. (2017). T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project. Clinical Cancer Research. 23(20). 6078–6085. 283 indexed citations

Tateishi, Kensuke, Fumi Higuchi, Julie J. Miller, et al.. (2017). The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1 -Mutant Cancers and Potentiates NAD+ Depletion–Mediated Cytotoxicity. Cancer Research. 77(15). 4102–4115. 73 indexed citations

Esaki, Shinichi, Fares Nigim, Juri Kiyokawa, et al.. (2017). Blockade of transforming growth factor‐β signaling enhances oncolytic herpes simplex virus efficacy in patient‐derived recurrent glioblastoma models. International Journal of Cancer. 141(11). 2348–2358. 37 indexed citations

Andronesi, Ovidiu C., Morteza Esmaeili, Ronald Borra, et al.. (2017). Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival. npj Precision Oncology. 1(1). 13 indexed citations

10.

Tateishi, Kensuke, A. John Iafrate, Quan Ho, et al.. (2016). Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma. Clinical Cancer Research. 22(17). 4452–4465. 119 indexed citations

11.

Jafari‐Khouzani, Kourosh, Franziska Loebel, Wolfgang Bogner, et al.. (2016). Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutantIDHglioma patients. Neuro-Oncology. 18(11). now100–now100. 30 indexed citations

12.

Andronesi, Ovidiu C., Franziska Loebel, Wolfgang Bogner, et al.. (2015). Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. Clinical Cancer Research. 22(7). 1632–1641. 116 indexed citations

13.

Gainor, Justin F., S. Andrew, Jennifer Logan, et al.. (2015). Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer Relapsing on Standard Dose Alectinib. Journal of Thoracic Oncology. 11(2). 256–260. 57 indexed citations

14.

Nigim, Fares, Jill Cavanaugh, Anoop P. Patel, et al.. (2015). Targeting Hypoxia-Inducible Factor 1α in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment. Journal of Neuropathology & Experimental Neurology. 74(7). 710–722. 30 indexed citations

15.

Gainor, Justin F., Carol A. Sherman, Jennifer Logan, et al.. (2015). Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib. Journal of Thoracic Oncology. 10(2). 232–236. 125 indexed citations

16.

Wakimoto, Hiroaki, Shota Tanaka, William T. Curry, et al.. (2014). Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH -Mutant Gliomas. Clinical Cancer Research. 20(11). 2898–2909. 130 indexed citations

17.

Sullivan, James P., Brian V. Nahed, Marissa W. Madden, et al.. (2014). Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression. Cancer Discovery. 4(11). 1299–1309. 200 indexed citations

18.

Taylor, Jennie, Jörg Dietrich, Elizabeth R. Gerstner, et al.. (2014). Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma. Journal of Neuro-Oncology. 121(3). 557–563. 29 indexed citations

19.

Rheinbay, Esther, Mario L. Suvà, Shawn Gillespie, et al.. (2013). An Aberrant Transcription Factor Network Essential for Wnt Signaling and Stem Cell Maintenance in Glioblastoma. Cell Reports. 3(5). 1567–1579. 197 indexed citations

20.

Reinisch, Carol L. & S. Andrew. (1978). Regulation of cytotoxic T-cell reactivity to syngeneic tumors by the thymus.. The Journal of Experimental Medicine. 148(2). 619–623. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact